Why Industry Partnerships Are Essential for Type 1 Diabetes Research

The development of new treatments for type 1 diabetes (T1D) has historically moved at a measured pace, constrained by funding limitations, fragmented research efforts, and the inherent complexity of an autoimmune disease. JDRF, the premier global organization funding T1D research, has recognized that the fastest path from laboratory discovery to patient bedside runs through strategic, deep-rooted collaborations with pharmaceutical and biotechnology companies. By pooling resources, sharing risk, and aligning incentives, these partnerships are reshaping the drug development pipeline for the 8.4 million people worldwide living with T1D.

Collaboration addresses a critical gap in the traditional drug development model. Early-stage academic discoveries often lack the capital and infrastructure required for large-scale clinical trials, manufacturing, and regulatory approval. Pharmaceutical companies, by contrast, possess these capabilities but may not have deep expertise in the specific biology of T1D or direct access to patient communities. JDRF serves as a bridge, connecting the research community with industry partners to accelerate progress toward a cure.

For a deeper look at the global burden of T1D and the urgency of new therapies, the JDRF facts page provides current statistics on disease prevalence and the impact on patients and families.

The Economics of Accelerated Drug Development

Bringing a single new drug to market now costs an estimated $1 billion to $2 billion and takes upwards of 10 to 15 years. For T1D, a disease that affects a smaller patient population compared to type 2 diabetes, the financial incentive for pharmaceutical investment can be less compelling. JDRF collaborations help de-risk early-stage research by funding proof-of-concept studies and providing access to patient registries, making it more attractive for industry partners to commit resources.

These partnerships reduce the time between target identification and clinical testing. When JDRF co-funds a project, the organization also brings scientific expertise in trial design, biomarker selection, and patient stratification. This collaborative approach helps pharmaceutical companies design more efficient trials with higher probabilities of success, saving years of development time and millions of dollars.

The economic argument extends beyond cost savings. By accelerating approval timelines, therapies reach patients sooner, reducing the long-term healthcare costs associated with complications of poorly managed T1D, including kidney disease, retinopathy, and cardiovascular events. A therapy approved even two years earlier can have a measurable impact on both patient outcomes and healthcare system expenditures.

Shared Risk, Shared Reward

One of the most effective models JDRF has championed is the shared-risk partnership. In this structure, JDRF provides initial grant funding for preclinical validation while the pharmaceutical partner contributes parallel resources for toxicology studies and manufacturing process development. If the candidate therapy shows promise, both parties share in the upside, with JDRF typically negotiating clauses that ensure patient access and affordability. If the candidate fails, the financial loss is distributed, encouraging companies to explore higher-risk but potentially higher-reward targets.

Key Areas of Partnership Between JDRF and Industry

JDRF's collaboration strategy spans the entire drug development lifecycle. Rather than limiting partnerships to a single stage, the organization engages with pharmaceutical companies at multiple points, from target discovery through post-market surveillance. This comprehensive approach ensures that promising therapies receive support at every critical juncture.

Research Funding and Target Validation

JDRF allocates significant resources to early-stage research funding, often supporting academic laboratories that have identified novel therapeutic targets but lack the means to validate them in relevant disease models. By funding this validation work, JDRF generates the data package that pharmaceutical companies need to evaluate a target's commercial potential. This de-risking is a key enabler for subsequent industry investment. In recent years, JDRF has funded research into beta cell regeneration, immune modulation, and antigen-specific therapies, all areas that have attracted pharmaceutical interest.

Clinical Trial Infrastructure and Patient Recruitment

Patient recruitment remains one of the most challenging aspects of T1D clinical trials. Many people with T1D are unaware of available trials or are reluctant to participate due to concerns about time commitment or potential side effects. JDRF leverages its extensive patient community and digital communication channels to raise awareness and facilitate enrollment. The organization also maintains detailed patient registries that allow researchers to identify candidates based on specific disease characteristics, such as age at onset, C-peptide levels, or genetic markers.

Pharmaceutical partners benefit from this infrastructure in two important ways. First, faster enrollment means trials can be completed months ahead of schedule, reducing overall costs. Second, JDRF's network includes underserved populations who are often underrepresented in clinical research, helping companies generate more inclusive data that supports broader labeling claims during regulatory review.

Data Sharing and Biomarker Development

Data sharing is a growing priority for JDRF and its industry partners. By agreeing to share aggregated clinical data, pharmaceutical companies gain access to a larger dataset for identifying biomarkers that predict treatment response or disease progression. These biomarkers can be used to enrich trial populations, ensuring that only patients most likely to benefit are enrolled. This approach not only increases trial efficiency but also minimizes patient exposure to ineffective therapies.

JDRF has been a leader in establishing data-sharing consortia that include multiple pharmaceutical companies, academic researchers, and regulatory agencies. These consortia work to standardize data collection methods, define common endpoints, and create repositories that are accessible to all participants. The result is a collaborative ecosystem where insights from one trial can inform the design of the next, accelerating the overall pace of discovery.

Regulatory Strategy and Market Access

Navigating the regulatory landscape is a formidable challenge for any new therapy. JDRF provides expertise in regulatory strategy, helping pharmaceutical companies design trial protocols that align with FDA and EMA expectations for T1D therapies. This guidance is especially valuable for novel modalities, such as cell therapies or gene editing approaches, where the regulatory framework is still evolving. JDRF also advocates for patient-centered endpoints that capture what matters most to people living with T1D, such as reduction in hypoglycemic episodes or improved quality of life, alongside traditional glycemic measures.

Examples of Successful Collaborations

The impact of JDRF's partnership model can be seen in several high-profile collaborations that have advanced from early-stage research to clinical testing.

Immune Therapies for Preservation of Beta Cell Function

One of the most active areas of partnership involves immune therapies designed to halt the autoimmune attack on insulin-producing beta cells. JDRF has collaborated with multiple biotechnology companies, including Provention Bio and others, to develop and test monoclonal antibodies and immunomodulatory agents that can preserve residual beta cell function at the time of diagnosis. The FDA approval of teplizumab, the first disease-modifying therapy for T1D, was a landmark achievement built on years of collaborative research involving JDRF funding, academic discovery, and pharmaceutical development.

Teplizumab was shown to delay the onset of clinical T1D in at-risk individuals by an average of two to three years, offering a new paradigm for early intervention. This success has opened the door to combination therapies that target multiple immune pathways simultaneously, a strategy that JDRF is actively exploring with several pharmaceutical partners.

Closed-Loop Insulin Delivery Systems

While not a cure, closed-loop insulin delivery systems, often called artificial pancreas systems, represent a transformative improvement in T1D management. JDRF provided early funding and advocacy for the development of these systems, supporting research at academic centers and collaborating with companies like Medtronic, Insulet, and Tandem Diabetes Care. The organization's work in defining the clinical trial endpoints that would satisfy regulatory requirements and payers was instrumental in bringing these devices to market.

Today, hybrid closed-loop systems are available to patients in many countries, and fully automated systems are in advanced development. JDRF continues to partner with device manufacturers on next-generation technologies, including dual-hormone systems that deliver both insulin and glucagon.

Beta Cell Replacement and Regeneration

Cell replacement therapy offers the promise of restoring insulin independence without the need for lifelong immunosuppression. JDRF has partnered with companies developing encapsulated beta cells derived from stem cells, as well as with organizations working on gene-edited cells that can evade the immune system. This partnership model has helped bridge the gap between academic stem cell biology and the manufacturing and clinical expertise that pharmaceutical companies provide. Several candidates are now in early clinical trials, representing a potential breakthrough in functional cure for T1D.

For additional perspective on how these partnerships affect the clinical trial ecosystem, the ClinicalTrials.gov database lists actively recruiting T1D studies, many of which are supported by JDRF-industry collaborations.

How JDRF Selects and Vets Partners

Building effective collaborations requires careful partner selection. JDRF employs a rigorous evaluation process that considers a company's scientific expertise, track record in drug development, commitment to patient access, and financial stability. Priority is given to companies that share JDRF's vision of accelerating safe and effective therapies to patients and that demonstrate willingness to collaborate on data sharing and patient engagement.

The organization also prioritizes partnerships that address unmet needs in T1D, such as therapies for children, approaches that preserve beta cell mass, and innovations that reduce the burden of daily disease management. Each potential partnership is reviewed by JDRF's scientific advisory committees to ensure alignment with the organization's strategic research priorities and to avoid duplication of effort across the research landscape.

The Role of the Research Portfolio

JDRF maintains a dynamic research portfolio that identifies gaps and emerging opportunities in the T1D pipeline. When a gap is identified, JDRF may actively seek industry partners with complementary capabilities. For example, if the portfolio reveals a shortage of therapies targeting the autoimmune component of T1D, JDRF might issue a request for proposals from biotechnology companies with expertise in antigen-specific immunotherapy. This proactive approach ensures that partnerships are strategic and not merely reactive to inbound interest.

Challenges in T1D Drug Development

Despite the progress made through collaboration, significant challenges remain. T1D is a heterogeneous disease, and therapies that work in one subset of patients may not work in another. Identifying the right patient population for each therapy requires sophisticated biomarkers that are still under development. Additionally, the safety bar for T1D therapies is exceptionally high, especially for interventions intended for children or for disease prevention in asymptomatic individuals. Regulators and patients alike expect therapies to have minimal side effects, which can limit the dose and duration of treatment.

Funding is another persistent challenge. While JDRF provides critical early-stage support, the cost of late-stage clinical trials and manufacturing scale-up often requires significant investment from pharmaceutical partners. Economic pressures, including pricing negotiations and reimbursement uncertainty, can slow or halt development even for promising candidates. JDRF works to address these barriers through advocacy for policies that support innovation and patient access, as well as by fostering public-private partnerships that share the financial burden of late-stage development.

The Future of JDRF and Pharmaceutical Partnerships

Looking ahead, JDRF plans to expand its collaboration model in several important directions.

Personalized Medicine

The growing understanding of T1D subtypes and genetic risk factors is opening the door to personalized treatment approaches. JDRF is working with pharmaceutical partners to develop companion diagnostics that identify which patients are most likely to respond to specific therapies. This precision medicine approach has the potential to improve trial success rates and deliver better outcomes for patients. In the future, individuals at risk for T1D may receive therapies tailored to their specific immune profile long before clinical symptoms appear.

Innovative Delivery Systems

Advances in drug delivery technology, including long-acting formulations, oral peptides, and implantable devices, are expanding the options for T1D treatment. JDRF is partnering with companies developing these technologies to ensure that new therapies can be delivered in ways that fit patients' lives. For example, a once-monthly injectable therapy or an oral medication that replaces daily insulin injections would dramatically change the treatment landscape. JDRF is also exploring partnerships focused on glucose-responsive insulin, or "smart insulin," that activates only when blood sugar levels rise.

Global Access and Equity

As new therapies emerge, ensuring equitable access remains a core priority for JDRF. The organization negotiates access provisions in its partnership agreements and advocates for pricing models that balance innovation with affordability. JDRF is also working to expand clinical trial access in low- and middle-income countries, where the burden of T1D is growing rapidly and where patients have historically been excluded from research. These efforts are supported by partnerships with global health organizations and local healthcare providers.

For more information on how health systems are adapting to new T1D therapies, the FDA consumer update on teplizumab provides an overview of the regulatory approval process for disease-modifying therapies.

Conclusion

JDRF's collaboration with pharmaceutical companies represents a powerful model for accelerating drug development in a complex disease area. By combining the organization's scientific expertise, patient networks, and advocacy influence with industry capabilities in manufacturing, clinical development, and regulatory affairs, these partnerships are turning scientific discoveries into real-world treatments faster than either sector could achieve alone.

The progress made to date, from the approval of the first disease-modifying therapy to the development of advanced insulin delivery systems, demonstrates the impact of this approach. With a continued focus on innovation, data sharing, and patient access, JDRF and its pharmaceutical partners are working together to transform the landscape of diabetes care and bring the promise of a cure closer to reality for millions of people worldwide.

To learn more about current research priorities and partnership opportunities, visit the JDRF Research page for detailed information on funded programs and strategic initiatives.